Synopsis: Jefferies has a Buy call on Sun Pharma, citing a potential 30% upside driven by the Organon acquisition, though higher leverage and limited R&D gains pose key risks. This large-cap Pharma Stock, engaged in developing, manufacturing, and marketing generic...
Synopsis: Shares of Sun Pharma fell 3 percent in a day’s trading session after the US Food and Drug Administration (US FDA) inspected the company’s Baska manufacturing facility, found a major compliance issue and classified it under Official Action...
Synopsis: The shares of Sun Pharma are in focus after Macquarie has initiated a Buy call on the stock, following its low exposure to the US. The shares of this leading pharmaceutical company are back in the spotlight after Macquarie sees 28 percent upside. In this...
The upcoming Sensex rebalancing in December represents a significant shift in India’s marquee index composition, reflecting evolving market dynamics and sector performance. For investors, these changes signal crucial portfolio adjustment opportunities and...
The pharmaceutical sector is one of the most dynamic sectors in India. Pharmaceutical products are focused on drugs, sprays, ointments, injections, creams, pills, and capsules. The Indian market is a major market for these products, with the pharma and consumer...
Fundamental Analysis of Sun Pharmaceutical: Sun Pharma is the largest pharma company in India and the 15th largest listed company in terms of market capitalization. Plus, its stock has generated a sweet return of more than 100% to its investors in the last five years,...
